Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Collection of Sputum and Labeling for Lung Cancer

bioAffinity Technologies Inc. · NCT03457415

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 21+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
500
US sites recruiting
3
Study start
March 1, 2018
Record last updated
April 1, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in accordance with findings of bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary to finalize Assay design for clinical trials and commercialization.

The secondary objective of this study is to determine optimum methods for collection of sputum samples. Three sputum collection methods used by high risk Participants will be compared. Individuals at high risk for lung cancer will be assigned to one of three sputum collection cohorts including (1) acapella® airway assist device under medical supervision to obtain a single sputum sample; (2) acapella® airway assist device to obtain a sputum sample over a three-day period, and (3) individuals who under medical supervision will collect a single sputum sample assisted by nebulization of between 0.9% to 10% hypertonic saline. Samples will be compared to determine the optimal collection method for sample analysis by CyPath® Lung.

Conditions: Lung Cancer

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Each subject must meet the following criteria to be enrolled in this study:

  • Male or female
  • 21 years of age or older
  • Willing to provide primary care physician contact information to the investigator and agree to have medical information released if indicated
  • Meet requirements of one of three cohorts in the study:

Healthy Cohort: Current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.

High Risk Cohort: Individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years, or current non-smoker who has a smoking history of at least 30 pack-years, and quit smoking within the past 15 years.

Cancer Cohort: Individual who has been diagnosed by a physician as highly suspect for having lung cancer but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from the study:

  • Severe obstructive lung disease and unable to cough with sufficient exertion to produce a sputum sample. Participants with lung disease that are able to cough with sufficient exertion to produce a sputum sample are not excluded from the study
  • Angina with minimal exertion
  • Pregnancy

Recruiting US locations

  • Atlantic Respiratory Institute

    Summit, NJ 07901

    Site contact: Marissa Rienton-Lim, CCRC · 908-934-0440 · marissa.rienton-lim@atlantichealth.org

  • Radiology Associates of Albuquerque

    Albuquerque, NM 87109

    Site contact: Timothy P. Zannes, JD · 505-506-0853 · tz@bioaffinitytech.com

  • South Texas Veterans Health Care System (STVHCS)/Audie L. Murphy Memorial Veterans Hospital

    San Antonio, TX 78229

    Site contact: Jennifer Whitehead · 210-834-1344 · Jennifer.Whitehead@va.gov

Study contacts (from the official record)

  • Maria Zannes, JD · 505-400-9747 · mz@bioaffinitytech.com
  • Xavier Reveles, MS · 210-698-5334 · xr@bioaffinitytech.com
Collection of Sputum and Labeling for Lung Cancer (NCT03457415) | Bored Studies